On April 1, 2025 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, reported the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5 (Press release, Oncopeptides, APR 1, 2025, View Source [SID1234655619]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Based on the company’s proprietary Peptide Drug Conjugate (PDC) platform, OPD5 is a follow-on molecule to Oncopeptides’ flagship drug melflufen (branded in Europe as Pepaxti) with a potentially improved risk/benefit profile and enhanced intellectual property protection. OPD5 would initially target multiple myeloma and could potentially be expanded with other indications and diseases over time.
"We continue to see a strong medical need for a PDC in the U.S. confirmed by leading experts in the country," says Sofia Heigis, CEO of Oncopeptides. "With the go-ahead from the regulator, we are now able to move ahead with plans for clinical development."
As a next step, Oncopeptides will continue to prepare for a new clinical study, OP-502, to assess the safety, tolerability and efficacy of OPD5. Given its similarities to melflufen and the experience gained from its’ U.S. approval process, Oncopeptides believes that OPD5 can fulfill an important medical need in U.S. as well as in the EU. To support continued development including a phase 1 study, the company is assessing various financing options, including partnerships.
For more information including a Q&A for investors, please visit Oncopeptides.com.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: [email protected]
Cell phone: +46 76 229 38 68